Johnson & Johnson (JNJ) reported Q3 FY 2020 earnings of $2.20 per share (versus $2.12 per share in Q3 FY 2019), beating analysts’ consensus estimate of $1.98 per share.

The company’s quarterly revenues amounted to $21.082 bln (+1.7% y/y), beating analysts’ consensus estimate of $20.155 bln.

The company also issued upside guidance for FY 2020, projecting EPS of $7.95-8.05 versus analysts’ consensus estimate of $7.89 and its prior guidance of $7.75-7.95 and revenues of +0.0-1.0% y/y to ~$82.0-82.8 bln versus analysts’ consensus estimate of $80.66 bln and its prior guidance of $79.9-81.4 bln.

JNJ fell to $150.28 (-1.03%) in pre-market trading.